AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Q4 2012 Earnings Presentation

28 slides from AVEO Pharmaceuticals's earnings presentation, Feb 13, 2013

  1. Slide 1: AVEO 4Q12 Results Conference Call and Tivozanib Update

    AVEO 4Q12 Results Conference Call and Tivozanib Update 1 February 13, 2013 Exhibit 99.1

  2. Slide 2: Tivozanib Update: Bill Slichenmyer, MD, Chief Medical Officer

    Tivozanib Update: Bill Slichenmyer, MD Chief Medical Officer 3 February 13, 2013

  3. Slide 3: TIVO-1: Phase 3 Superiority Study of Tivozanib vs. Sorafenib

    TIVO-1: Phase 3 Superiority Study of Tivozanib vs. Sorafenib as First-line Targeted Therapy for Advanced RCC

  4. Slide 4: TIVO-1 Primary Endpoint: PFS by Independent Review

    Overall TIVO-1 Primary Endpoint: PFS by Independent Review Treatment Naïve for Metastatic RCC n Median PFS (95% CI) HR P Value Tivozanib 11.9 mos (9.3-14.7) 0.797 0.042 Sorafenib 9.1 mos (7.3-9.5) n Median PFS (95% CI) HR P Value Tivozanib 12.7 mos (9.1-15.0) 0.756 0.037 Sorafenib 9.1 mos (7.3-10.8)

  5. Slide 5: Tivozanib Safety Profile

    February 12, 2013 • >1,000 subjects treated with tivozanib • Lower rates than sorafenib for common adverse events and dose modifications • Rate of fatal AEs consistent with reports from past pivotal RCC trials Dose Adjustments Motzer, et al., ASCO 2012 * Due to AE’s **Due to treatment-related AE’s T

  6. Slide 6: 2013 ASCO GU Symposia: TIVO-1 Data Presentations

    2013 ASCO GU Symposia: TIVO-1 Data Presentations

  7. Slide 7: Overall Survival in TIVO-1: Motzer et al.

    Overall Survival in TIVO-1: Motzer et al. Abstract #350

  8. Slide 8: Protocol-Specified, Final OS Analysis

    Protocol-Specified, Final OS Analysis Final OS analysis conducted, per protocol, at two years following last patient enrolled (August 2012) 0.4% 8.3% 15% 21% 28% 37% 43% 48% 53% 57% 59% 61% 67% 58% 100% % of control arm pts crossed over to tivozanib Time (months)

  9. Slide 9: Use of Next-Line Treatments

    Use of Next-Line Treatments *Other includes radiotherapy, cytokine or other therapy

  10. Slide 10: OS in Patients from North America/Western Europe

    OS in Patients from North America/Western Europe

  11. Slide 11: Use of Next-line Therapies in North America/Western Europe

    Use of Next-line Therapies in North America/Western Europe *Other includes radiotherapy, cytokine or other therapy

  12. Slide 12: Next-line Therapy and Overall Survival

    Next-line Therapy and Overall Survival Motzer, et al. Abstract #350, continued

  13. Slide 13: Subset of Patients Who Have Received No Next-Line Therapy: 1 vs 1

    Subset of Patients Who Have Received No -Line Therapy: “1 vs 1” HR=0.917 P “1 vs 1 treatment” =0.662 nd

  14. Slide 14: Analysis of "2 vs 2" Lines of Treatment: Next-line VEGF Only

    OS Analysis of “2 vs 2” Lines of Treatment: Next-line VEGF Treatment Only HR=1.37 % of patients with next-line anti-VEGF therapy 70% anti-VEGF 10% anti-VEGF P =0.382

  15. Slide 15: Analysis of "2 vs 2" Lines of Treatment: Any Anticancer Treatment

    OS Analysis of “2 vs 2” Lines of Treatment: Any Anticancer Treatment HR=1.58 P =0.027 % of patients with next-line other/VEGF/mTOR therapy 18% other 10% VEGF 8% mTOR 3% other 70% VEGF 2% mTOR

  16. Slide 16: Tivozanib in Line Following Sorafenib: Motzer et al.

    Tivozanib in 2 Line Following Sorafenib: Motzer et al. nd Abstract #364

  17. Slide 17: Change From Baseline for Target Lesions

    Change From Baseline for Target Lesions (Investigator Assessment) 141 patients had measurable disease at baseline and at least one subsequent scan *9 additional unconfirmed responses ORR (confirmed + unconfirmed) = 19% Overall Response Rate (confirmed)* = 13%

  18. Slide 18: PFS and OS for Patients Receiving Tivozanib after Sorafenib

    PFS and OS for Patients Receiving Tivozanib after Progression on Sorafenib Median PFS = 8.4 months 95% CI: 5.5-12.4 Median OS = 19.6 months 95% CI: 14.1-NA tivozanib % PFS % OS tivozanib

  19. Slide 19: Subgroup Analyses from TIVO-1: Hutson et al.

    Subgroup Analyses from TIVO-1: Hutson et al. Abstract #354

  20. Slide 20: Forest Plot of PFS Hazard Ratios by Independent Radiological Review

    Forest Plot of PFS Hazard Ratios by Independent Radiological Review Assessment a MSKCC and Heng “poor” prognostic subgroups too small to estimate HR; therefore exclude b By independent radiological review assessment

  21. Slide 21: PFS by Prior Treatment History

    PFS by Prior Treatment History Time (months) Time (months) No prior systemic therapy for metastatic disease One prior systemic therapy for metastatic disease

  22. Slide 22: PFS in North America/Western Europe and Central Europe

    PFS in North America/Western Europe and Central Europe Time (months) Time (months) Central / Eastern Europe North America / Western Europe

  23. Slide 23: PFS by ECOG Performance Status Score

    ECOG Score 0 ECOG Score 1 Time (months) Time (months) Tivozanib arm 14.8 (11.3–NR) N Median PFS (95% CI) HR P value 0.617 0.004 Sorafenib arm 9.1 (7.5–11) Tivozanib arm 9.1 (7.5–12.9) N Median PFS (95% CI) HR P value 0.920 0.588 Sorafenib arm 9 (7.2–10.9) PFS by ECOG Performance Status Score

  24. Slide 24: PFS by MSKCC Favorable or Intermediate Score

    PFS by MSKCC Favorable or Intermediate Score Time (months) Time (months) MSKCC intermediate MSKCC favorable MSKCC “poor” prognostic subgroup too small to estimate HR, therefore excluded

  25. Slide 25: On Study BP and PFS

    On-study BP, mm Hg Tivozanib Sorafenib mPFS (95% CI) n mPFS (95% CI) n P value SBP 140 SBP >140 DBP 90 DBP >90 On Study BP and PFS 9.0 (7.2–11.3) 5.8 (5.5–9.0) 0.142 16.7 (12.9–18.3) 11.1 (9.2–14.7) 0.076 9.1 (7.5–12.7) 7.3 (5.7–9.1) 0.156 18.3 (12.9–NA) 11.0 (9.3–16.4) 0.154

  26. Slide 26: Quality of Life Results from TIVO-1: Cella et al.

    Quality of Life Results from TIVO-1: Cella et al. Abstract #355

  27. Slide 27: More Patients Experience Health-related QOL Improvement on Tivozanib

    More Patients Experience Health-related QOL Improvement on Tivozanib than on Sorafenib Across Most QOL Domains • Numeric differences favoring tivozanib were observed regarding improvement rates across all subgroups and HRQoL scores, except Social Well Being (SWB). • Statistically significant differe

  28. Slide 28: AVEO 4Q12 Results Conference Call and Tivozanib Update

    AVEO 4Q12 Results Conference Call and Tivozanib Update 33 February 13, 2013

AVEO Pharmaceuticals — Q4 2012 Earnings Presentation on 6ix